Understanding how drug-resistant glioma cells die
Ferroptosis in drug resistant glioma
['FUNDING_CAREER'] · NORTHWESTERN UNIVERSITY AT CHICAGO · NIH-10931554
This study is looking into why some glioblastoma brain tumors stop responding to treatment, focusing on how these tough cells use nutrients and iron differently, with the hope of finding new ways to make them more vulnerable to therapies that could help patients.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHWESTERN UNIVERSITY AT CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-10931554 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms behind drug resistance in glioblastoma, a deadly brain tumor. It focuses on the differences in metabolism between drug-sensitive and drug-resistant glioma cells, particularly how these cells rely on certain nutrients and iron. By exploring a specific type of cell death called ferroptosis, the study aims to identify new treatment strategies that could target vulnerabilities in resistant glioma cells. Patients may benefit from insights that could lead to more effective therapies for glioblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have shown resistance to standard chemotherapy treatments.
Not a fit: Patients with glioblastoma who are newly diagnosed and have not yet undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve survival rates for patients with drug-resistant glioblastoma.
How similar studies have performed: Previous research has shown promise in targeting metabolic vulnerabilities in cancer cells, suggesting that this approach could yield significant results.
Where this research is happening
CHICAGO, UNITED STATES
- NORTHWESTERN UNIVERSITY AT CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TIEK, DEANNA MARIE — NORTHWESTERN UNIVERSITY AT CHICAGO
- Study coordinator: TIEK, DEANNA MARIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Brain Cancer